Information Journal Paper
APA:
Copy. (2018). Immunotherapy: Tisagenlecleucel-the first approved CAR-T-cell therapy: implications for payers and policy makers. NATURE REVIEWS CLINICAL ONCOLOGY, 15(1), 11-12. SID. https://sid.ir/paper/724613/en
Vancouver:
Copy. Immunotherapy: Tisagenlecleucel-the first approved CAR-T-cell therapy: implications for payers and policy makers. NATURE REVIEWS CLINICAL ONCOLOGY[Internet]. 2018;15(1):11-12. Available from: https://sid.ir/paper/724613/en
IEEE:
Copy, “Immunotherapy: Tisagenlecleucel-the first approved CAR-T-cell therapy: implications for payers and policy makers,” NATURE REVIEWS CLINICAL ONCOLOGY, vol. 15, no. 1, pp. 11–12, 2018, [Online]. Available: https://sid.ir/paper/724613/en